Journal article · 2026 · Open access

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study

Takashi Nakano, Satoshi Iwata, Kazunori Oishi, Eriko Iguchi, Yumi Suganuma, Yukio Tada, Shouta Saiki, Kumi Hashimoto, Hitomi Nakajima-Yoshida, Shinya Omoto, Tatsuya Yazaki, Takuhiro Sonoyama

Vaccine, 88, 128871 · Published 3 July 2026 · DOI 10.1016/j.vaccine.2026.128871

Open PDFView at the publisherCite this paper

In brief

“Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study” is a 2026 journal article by Takashi Nakano and 11 co-authors, published in Vaccine. OpenAlex counts 1 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at Vaccine.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
3.08
References
14
Authors
12

Abstract

BACKGROUND: S-268024 is a recombinant protein vaccine developed as a COVID-19 booster. METHODS: This randomized, observer-blind, phase 3 study enrolled previously vaccinated Japanese adults without a history of SARS-CoV-2 infection. The noninferiority of the immunogenicity of the S-268024 booster vaccination versus NVX-CoV2373 was assessed. RESULTS: The immunogenicity population included 733 (S-268024 group: n = 368; NVX-CoV2373 group: n = 365) of 734 randomized participants. The geometric mean titer (GMT) ratio (95% confidence interval [CI]) was 1.79 (1.52-2.12), and the difference in seroresponse rate (95% CI) of SARS-CoV-2 neutralizing antibody was 7.9% (1.3%-14.4%) on day 29. The lower limit of 95% CI exceeded prespecified margins, indicating noninferior immunogenicity of S-268024 versus NVX-CoV2373; superiority in GMT was also demonstrated. Treatment-related adverse events (AEs) were numerically higher with S-268024 (92.4%) than NVX-CoV2373 (77.5%), with no treatment-related deaths/serious AEs/AEs of special interest. CONCLUSIONS: Interim analyses established noninferiority and superiority of S-268024 to NVX-CoV2373 in immunogenicity, with an acceptable safety profile.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Nakano, T., Iwata, S., Oishi, K., Iguchi, E., Suganuma, Y., Tada, Y., Saiki, S., Hashimoto, K., Nakajima-Yoshida, H., Omoto, S., Yazaki, T., & Sonoyama, T. (2026). Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study. Vaccine, 88, 128871. https://doi.org/10.1016/j.vaccine.2026.128871

MLA 9

Nakano, Takashi, et al. “Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.” Vaccine, vol. 88, 2026, p. 128871. https://doi.org/10.1016/j.vaccine.2026.128871.

Chicago

Nakano, Takashi, Satoshi Iwata, Kazunori Oishi, Eriko Iguchi, Yumi Suganuma, Yukio Tada, Shouta Saiki, et al. 2026. “Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.” Vaccine 88: 128871. https://doi.org/10.1016/j.vaccine.2026.128871.

Harvard

Nakano, T. et al. (2026) ‘Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study’, Vaccine, 88, p. 128871. doi:10.1016/j.vaccine.2026.128871.

IEEE

T. Nakano et al., “Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study,” Vaccine, vol. 88, p. 128871, 2026, doi: 10.1016/j.vaccine.2026.128871.

BibTeX

@article{nakano2026immunogenicity,
  title     = {{Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study}},
  author    = {Nakano, Takashi and Iwata, Satoshi and Oishi, Kazunori and Iguchi, Eriko and Suganuma, Yumi and Tada, Yukio and Saiki, Shouta and Hashimoto, Kumi and Nakajima-Yoshida, Hitomi and Omoto, Shinya and Yazaki, Tatsuya and Sonoyama, Takuhiro},
  journal   = {Vaccine},
  year      = {2026},
  volume    = {88},
  pages     = {128871},
  doi       = {10.1016/j.vaccine.2026.128871},
  url       = {https://doi.org/10.1016/j.vaccine.2026.128871}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research

  • NVX-CoV2373
  • COVID-19 booster vaccination
  • recombinant protein vaccine
  • SARS-CoV-2
  • non-inferiority
  • immunogenicity
  • neutralizing antibodies
  • seroresponse

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Nakano, T., Iwata, S., Oishi, K., Iguchi, E., Suganuma, Y., Tada, Y., Saiki, S., Hashimoto, K., Nakajima-Yoshida, H., Omoto, S., Yazaki, T., & Sonoyama, T. (2026). Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study. Vaccine, 88, 128871. https://doi.org/10.1016/j.vaccine.2026.128871

How many times has this paper been cited?

1 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Vaccine: sign in and open the PDF from this page.

Who wrote this paper?

Takashi Nakano, Satoshi Iwata, Kazunori Oishi, Eriko Iguchi, Yumi Suganuma, Yukio Tada, Shouta Saiki, Kumi Hashimoto, Hitomi Nakajima-Yoshida, Shinya Omoto, Tatsuya Yazaki, Takuhiro Sonoyama.

What is the DOI of this paper?

10.1016/j.vaccine.2026.128871, permanently at https://doi.org/10.1016/j.vaccine.2026.128871. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.